Acyl-CoA Synthetase Isoforms 1, 4, and 5 Are Present in Different Subcellular Membranes in Rat Liver and Can Be Inhibited Independently

• Published in: The Journal of biological chemistry 2001-07, Vol.276 (27), p.24674-24679
• Main Authors: Lewin, T M, Kim, J H, Granger, D A, Vance, J E, Coleman, R A
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Antibody Specificity; Chromans - pharmacology; Coenzyme A Ligases - antagonists & inhibitors; Dietary Sucrose - pharmacology; Ethylmaleimide - pharmacology; Fasting; Intracellular Membranes - enzymology; Liver - enzymology; Mitochondrial Proteins; Molecular Sequence Data; Rats; Subcellular Fractions - enzymology; Thiazoles - pharmacology; Thiazolidinediones; Triazenes - pharmacology; Triglycerides - biosynthesis; Troglitazone
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M102036200

Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC 6.2.1.3 ) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5. ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane. Consistent with these locations, N -ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity